Supplementary Figure 2. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis
figureposted on 15.10.2021, 15:08 by Saaya Tsutsué, Takahiro Suzuki, Hyojin Kim, Bruce Crawford
Supplementary Figure 2. Total and cost categories by 12-month period for each regimen group. (A) [Transfusion], (B) [ESA], (C) [ESA + transfusion], (D) [AZA], (E) [AZA + transfusion], (F) [Other] regimens. AZA, azacitidine; ESA, erythropoiesis-stimulating agents; ICU, intensive care unit.